# Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

> **NCT06833112** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital Of Guizhou Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT06833112
- **Lead sponsor:** The Affiliated Hospital Of Guizhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2027-08
- **Final completion:** 2028-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833112, "Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06833112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*